Cardiac risk in the treatment of breast cancer: assessment and management.

Breast Cancer (Dove Med Press) · 2015 · PMC4303336 · PMID 25653554

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

However, there was a nonsignificant trend toward lower response rates among those who received anthracycline plus dexrazoxane. 38 Considering the lack of clinical data on dexrazoxane in the adjuvant setting and the concerns about potential impact on antitumor efficacy, dexrazoxane is not recommended for use in early breast cancer.

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.